134 related articles for article (PubMed ID: 35927344)
1. Daratumumab for the treatment of refractory idiopathic multicentric Castleman disease: a case report.
Shi Y; Li J; Zhang L
Ann Hematol; 2022 Nov; 101(11):2529-2531. PubMed ID: 35927344
[No Abstract] [Full Text] [Related]
2. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
van Rhee F; Rossi JF; Simpson D; Fosså A; Dispenzieri A; Kuruvilla J; Goh YT; Cho SG; Capra M; Liu T; Casper C; Cavet J; Wong RS
Br J Haematol; 2021 Jan; 192(1):e28-e31. PubMed ID: 33128769
[No Abstract] [Full Text] [Related]
3. Siltuximab for Multicentric Castleman Disease-Letter.
Teipel R; Ordemann R; Proske U; Dietrich F; Mende M; Ehninger G; Kroschinsky F; Platzbecker U
Clin Cancer Res; 2015 Oct; 21(20):4740. PubMed ID: 26473194
[No Abstract] [Full Text] [Related]
4. Efficacy of siltuximab in the treatment of idiopathic multicentric castleman disease, the first Polish, real-world experience with long-term observation.
Ostrowska B; Szymczyk A; Olszewska-Szopa M; Romejko-Jarosińska J; Domańska-Czyż K; Dąbrowska-Iwanicka A; Tomczak W; Rybski S; Hus M; Wróbel T; Walewski J
Leuk Lymphoma; 2021 Dec; 62(12):3031-3034. PubMed ID: 34159888
[No Abstract] [Full Text] [Related]
5. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
6. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
7. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
[TBL] [Abstract][Full Text] [Related]
8. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease.
Fragasso A; Mannarella C; Ciancio A; Calvario A; Scarasciulli ML
Leuk Lymphoma; 2008 Nov; 49(11):2224-6. PubMed ID: 19021070
[No Abstract] [Full Text] [Related]
9. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
[TBL] [Abstract][Full Text] [Related]
10. van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
Blood Adv; 2023 Apr; 7(8):1604-1605. PubMed ID: 37097712
[No Abstract] [Full Text] [Related]
11. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of multicentric Castleman's disease with bilateral orbital tumour using rituximab.
Ide M; Ogawa E; Kasagi K; Kawachi Y; Ogino T
Br J Haematol; 2003 Jun; 121(5):818-9. PubMed ID: 12780800
[No Abstract] [Full Text] [Related]
13. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
14. Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy.
Bayram E; Pehlivan UA; Fajgenbaum DC; Paydas S
Am J Hematol; 2023 Feb; 98(2):361-364. PubMed ID: 36401154
[No Abstract] [Full Text] [Related]
15. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
17. The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K; Murayama S; Ito H; Koga T
Hematol Oncol Clin North Am; 2018 Feb; 32(1):23-36. PubMed ID: 29157617
[TBL] [Abstract][Full Text] [Related]
18. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
[TBL] [Abstract][Full Text] [Related]
19. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
20. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
